ABSTRACT
of airways leading to breathlessness. It has shown growing trends all over the world including developing countries such as India. [1, 2] It is the fourth leading cause of the death [3] and major morbidity factor for increased cost and healthcare burden in the society. [4, 5] The data for its early diagnosis are lacking which pose a major obstacle for its prevention, treatment decision making and further management outcomes. [6] It has been categorized into different severities by Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines and American Thoracic
INTRODUCTION
The chronic obstructive pulmonary disease (COPD) is categorized as progressive obstructive limitation Society (ATS)/European Respiratory Society (ERS) guidelines. [1, 7] The long acting bronchodilators are preferred over the short acting bronchodilators. [1] There is increased use of fixed dose combinations of long acting muscarinic antagonists (LAMA) and long acting β 2 agonists (LABA) for its treatment. [8] They have been excitingly used in COPD patients within all the severities and thought to impact the treatment process. [9] Although there are conflicting data regarding the efficacy of combination of tiotropium and salmeterol [10] [11] [12] but the addition of formoterol with tiotropium also have not shown consistent outcomes. [12, 13] The developing countries such as India vehemently prescribe such fixed dose combinations and has become the first country to approve the marketing authorization to the triple inhaler. [8, 14] One such combination uses formoterol having 12 hours duration of action [15] and tiotropium having 24 hours. [16] Certainly such combinations increase the cost of therapy and financial burden on the healthcare system and may lead to poor patients' compliance in developing countries. [1] The present study was done to evaluate the effectiveness of three different regimens consisting of tiotropium and formoterol combinations in moderate COPD patients so that to observe the 12 hour as well as 24 hour protection by the LABA along with 24 hour acting LAMA.
MATERIAL AND METHODS

Participants
A total of 42 patients were enrolled in the study after Institutional Ethical Committee (IEC) approval from Vallabhbhai Patel Chest Institute, Delhi. All the patients were diagnosed with the help of spirometry and clinical symptomatology. Those having forced expiratory volume in 1 s (FEV 1 )/ forced vital capacity (FVC) ratio less than 0.7 and FEV 1 percentage predicted in the range of ≥50 to <80 were categorized as moderate COPD patients as per the GOLD guidelines criteria. [1] All the enrolled patients were ≥35 years of age who were current or exsmoker having smoking history of ≥10 pack years. The patients were excluded from the study if there was history of significant disease of cardiovascular system apart from the COPD such as recent history of myocardial infarction, heart failure, and cardiac arrhythmias. The patients were also not taken in the study if there was current or past history of asthma, allergic conditions, taking oxygen therapy, known to have a diagnosis of benign hyperplasia of prostate, narrow angle glaucoma, other respiratory infections, and COPD exacerbations in last 4 weeks.
Allocation
Once the diagnosis of COPD was made clinically and with the help of diagnostic spirometry 30 min after the two puffs of 100 µg salbutamol, the other baseline investigations such as complete hemogram, chest X-ray, and electrocardiogram (ECG) were done. The patients were allocated to one of the three computer-generated randomized groups and training of dry powder inhalation intake was given. They were asked to come next day in the morning at 8 AM for 24 h hospital admission under the supervision of principal investigator. Those patient who had taken short-acting bronchodilators just before the enrolment or long-acting bronchodilators at least 48 h before were not allowed to take part in the study. The study was made double blind by keeping the principal investigator (doctor), patients, and spirometry technicians blind. All the three treatment arms had active drugs in the morning and two of them had formoterol-matched placebo in the evening. The study was planned for 1 year and all the moderate COPD patients who came in that year were enrolled, thus exceeding 12 patients in each arm. It was completed in 1 year in 2008.
Protocol changes
The comorbidities are usually associated with higher age group COPD patients and they impact the net mortality and hospitalization. [17] It was difficult to find COPD patients without comorbidity, thus age criteria was relaxed with the proper approval of the IEC from 35 to 60 years to 35 years and above.
Data collection
The medication was administered and serial spirometry was done after written informed consent from the patients. The three groups were categorized as R1 (morning tiotropium + evening placebo-matched for formoterol), R2 (morning tiotropium and formoterol + evening placebo-matched for formoterol), and R3 (morning tiotropium and formoterol + evening formoterol). The patients were stayed in the ward of Clinical Research Centre (CRC) of University teaching tertiary care pulmonary medicine hospital, Delhi, India for 1 day and one night under the supervision of principal investigator. Each patient was assigned to the subsequent group as per their order of diagnosis. The biostatistician of the institute maintained the blinding by providing air-sealed container containing the dry powder capsules for each patient. The containers were opened and inhaled in the supervision of the principal investigator. The measurement of FEV 1 , FVC, Borg's perceptional dyspnea score, [18] blood pressure, and pulse rate was done at the baseline followed by the scheduled time points on 30 min, 2 h, 12 h after morning dose and 30 min and trough values 12 h after the evening dose. The highest values from three technically adequate readings based on ATS criteria were retained. The primary efficacy end points were defined as the improvement or change in FEV 1 , FVC, and dyspnea. And secondary end points were FEV 1 , FVC peak and trough values, and other spirometry values at individual time points. Apart from this second outcome parameters such as rescue therapy with salbutamol, sleep disturbances and adverse events were measured during the 24 h of the stay of the patients in the hospital.
Statistical analysis
The intra-and intergroup statistical analysis was done with the help of Statistical Package for Social Sciences (SPSS) 20 software. The hierarchical repeated measures analysis of variance (ANOVA) used adjusted means values for calculation followed by Tukey's test. The total sample size was 36 patients; 12 in each group. But patient enrolment continued to get the large number of patients within the stipulated time period of 1 year. There were 42 completed participants; 13 in R1, 15 in R2; and 14 in R3.
RESULTS
The moderate COPD patients without comorbidity underwent spirometry as per the protocol. Around 1,435 patients screened and classified as per the GOLD guidelines; [1] out of which 42 patients turned out to moderate COPD without any comorbidity. All patients who completed the study were male with average age of 47.45 ± 11.12. Table 1 shows the demographic and other baseline characteristics of the participants including average numbers of 'pack years' (calculated by multiplying the number of packs of cigarette smoked by a person per day to the number of years). The therapeutic effects of three different regimens were measured on 30 min, 2 h, 12 h, 12 h 30 min, and 24 h based on the pharmacological effects. [15, 16] The FEV 1 , FVC, Borg's Scale values, and vitals data were obtained. The data was decoded and analyzed by the statistician.
The 24 h mean values of FEV 1 (liters) in R1, R2, and R3 are 1.836 ± 0.51, 1.886 ± 0.47, and 1.805 ± 0.37, respectively. R1 showed significant improvement in FEV 1 at 30 min (1.717 ± 0.40) and trough values (24 h value) also showed an incremental increase upto 1.836±0.51 [ Table 2 ]. The effects of R2 regimens did not sustain till 24 h and the trough values fell below the 12 h values in that regimen. Same effects were observed in R3 except that the 24 h values were numerically superior to other regimen, although there was no statistical significance (1.805 ± 0.37).
When magnitude of difference (∆) with the baseline was assessed statistically, there was no statistical significance in ∆FEV 1 (liters), ∆FVC (liters), ∆FEV 1 % predicted, and ∆FVC % predicted values. Figures 1 and 2 shows the magnitude of difference (∆) in FVC in liters (FVC (L)) and FVC in % predicted versus the magnitude of difference time points 1,2,3,4, and 5; which corresponds to difference between the baseline and 30 min, 2 h, 12 h, 12:30 h, and 24 h values. There is no significant difference in all the time points except the 24 h mean FVC% predicted value which corresponds to P -value between 0.05 and 0.1. The Borg's Scale of perceptional dyspnea score showed a persistent significant improvement at each time point throughout the 24 h time period. The vitals did not show any significant changes during the observation period. All the participants were well-tolerated on Values are presented mean±SD (number). COPD=Chronic obstructive pulmonary disease, FEV 1 =Forced expiratory volume in 1 s, FVC=Forced vital capacity, BMI=Body mass index, R1=Tiotropium (morning) and formoterol-matched placebo (evening), R2=Tiotropium+formoterol (morning) and formoterol-matched placebo (evening), R3=Tiotropium+formoterol (morning) and formoterol (evening), SD=Standard deviation. ¶ 30 min following two puffs of Salbutamol (100 µg/puff) each treatment regimens. There was no use of rescue therapy with salbutamol and no incidents of any adverse events such as tremors and sleep disturbances were seen.
DISCUSSION
The findings of present study revealed that there is no advantage of adding formoterol once a day as well as twice a day along with the tiotropium in moderate COPD patients. It simply reflects that titrated tiotropium alone is an appropriate and rationale therapy in moderate category of COPD patients. This may be because of the predominance of parasympathetic system as a part of etiopathogenesis. [19] The addition of LABA drugs either for 12 h period such as formoterol and salmeterol or for 24 h such as indacaterol along with LAMA may not prove to have an additional favorable statistical outcome. [20, 21] As per our findings, the trough values in R3 are found to be numerical superior in comparison to R1 and R2, but there was not much statistical significance.
Although GOLD guidelines 2014 recommends the use of long-acting bronchodilators over the short-acting bronchodilators; but it admits the lack of screening data for making management decisions in early COPD categories. [1] Many studies have provided the conflicting data for the usage of LABA along with LAMA.
[10- 15, 20, 21] However, appropriate intervention and evidence-based medicine may provide favorable clinical or economic outcomes. [1] We conducted our study as randomized double-blind controlled clinical academic trial (RCT) with three parallel arms to eliminate the unrecognized biases in patient enrolment as this design has an advantage in drug intervention trials.
Limitation of the study
Despite being it a RCT, there were many limitations in our study. It was an acute study with less numbers of subjects in a single center, and therefore more number of subjects in multicentric sites along with long-term study design may provide exact clinical applicable results. Our study was double blind, hence many of the potential confounding factors such as baseline FEV 1 , FVC, age, and pack years could not be matched before the start of the investigations. In addition to the open label design, more number of serial datapoints can be incorporated so that wide variability can be captured in the study. Further studies obviating the limitation of present study may lead to understanding about the rationale treatment for different categories of COPD patients, compliance to the therapy and reducing the cost and burden of therapy on the society.
CONCLUSION
It can be concluded that each category of patients can be considered as separate subset of population and they need individualization of therapy as per the severity. In moderate COPD patients, tiotropium alone is efficacious and appropriate evidence-based therapy. Therefore, the 1.805±0.37* † § ¶ * † § ¶ (P<0.05), *Significant difference from baseline, † Significant difference from 30 min, § Significant difference from 2 h, ¶ Significant difference from 12 h. COPD=Chronic obstructive pulmonary disease, R1=Tiotropium (morning) and formoterol-matched placebo (evening), R2=Tiotropium+formoterol (morning) and formoterol-matched placebo (evening), R3=Tiotropium+formoterol (morning) and formoterol (evening)
